Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been first-line therapy in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR sensitive mutations. Progression inevitably happens after 10–14 months of first- or second-generation EGFR TKIs treatment for acq...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Leilei, Ke, Linping, Zhang, Zhenshan, Yu, Jinming, Meng, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775519/
https://www.ncbi.nlm.nih.gov/pubmed/33392095
http://dx.doi.org/10.3389/fonc.2020.602762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775519/
https://www.ncbi.nlm.nih.gov/pubmed/33392095
http://dx.doi.org/10.3389/fonc.2020.602762

Ejemplares similares